Opis projektu
Technologia mikrofalowa na potrzeby badań przesiewowych w kierunku raka piersi
W wielu krajach badania przesiewowe w kierunku raka piersi u kobiet w wieku powyżej 40 lat, które znajdują się w grupie ryzyka zachorowania, są wykonywane przy użyciu mammografii, techniki opartej na promieniowaniu jonizującym. Chociaż może ona pomóc w wykryciu raka piersi na wczesnym etapie, technologia ta nie jest odpowiednia dla piersi o radiograficznej gęstości tkanki. Aby zaradzić temu ograniczeniu, zespół finansowanego przez UE projektu MammoScreen proponuje wykorzystanie do badań przesiewowych piersi MammoWave, nieinwazyjnej technologii wykorzystującej niejonizujące sygnały mikrofalowe. W przeciwieństwie do mammografii, technologia MammoWave nie uciska piersi i jest bardzo skuteczna w przypadku gęstej tkanki piersi, dzięki czemu jest odpowiednia dla młodszych kobiet w wieku poniżej 40 lat.
Cel
Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Research on Cancer estimate that in 2020 worldwide cases of breast cancer accounted for 24% of all cancers in women (2.26 million women and 685,000 deaths globally). Mammography is the gold standard technology for breast screening, which has been demonstrated through different randomized controlled trials to reduce breast cancer mortality. However, it has limitations and potential harms, such as the use of ionizing radiation, breast compression and performance restrictions due to the intrinsic nature of X-rays. In particular, breast density is a restrictive property that can prevent breast cancer detection in mammograms of women with radiographically dense breasts. Other existing techniques (MRI, Ultrasound, biopsy) also suffer from drawbacks. The overall aim of the MammoScreen proposal is to generate evidence about the use of MammoWave (a technology developed by UBT) as screening technique in population-based programs promoted by National or Regional Health Systems, to reach a revolution in breast screening. To do so, the consortium aims to confirm that MammoWave reaches sensitivity>90% and specificity>95% in BC detection on 10000 study participants undergoing regular screening programs. MammoWave uses safe non-invasive and non-ionizing microwave signals, does not apply any compression to the breast and is very effective with dense breasts. Hence it can extend the breast screening to younger women aged 20-49 (98 million women in Europe). This group accounts for ~30% of breast cancers in 2020. A comprehensive health economic assessment will be undertaken in this project and innovative way to implement patient engagement approaches is sought. An effective policy makers’ engagement plan will be carried out to ensure that MammoWave is recommended as screening approach due to the benefits that it brings to women and healthcare systems. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.
Dziedzina nauki
Słowa kluczowe
Program(-y)
- HORIZON.2.1 - Health Main Programme
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
HORIZON-RIA - HORIZON Research and Innovation ActionsKoordynator
53100 Siena
Włochy